Trastuzumab (Herceptin)

J.J. Gemmete; S.K. Mukherji

doi:10.3174/ajnr.A2619

Main menu

Home
Content
Special Collections
Multimedia
For Authors
About Us
- About AJNR
- Editorial Board
More

Other Publications
- ajnr

User menu

Alerts
Log in

Search

Search for this keyword

Advanced search

American Journal of Neuroradiology

Alerts
Log in

Search for this keyword

Advanced Search

Home
Content
Special Collections
Multimedia
For Authors
About Us
- About AJNR
- Editorial Board
More

Follow AJNR on Twitter
Visit AJNR on Facebook
Follow AJNR on Instagram
Join AJNR on LinkedIn
RSS Feeds

Welcome to the new AJNR, Updated Hall of Fame, and more. Read the full announcements.

AJNR is seeking candidates for the position of Associate Section Editor, AJNR Case Collection. Read the full announcement.

Getting new auth cookie, if you see this message a lot, tell someone!

Research ArticlePharmacology Vignette

Trastuzumab (Herceptin)

J.J. Gemmete and S.K. Mukherji

American Journal of Neuroradiology September 2011, 32 (8) 1373-1374; DOI: https://doi.org/10.3174/ajnr.A2619

J.J. Gemmete

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

S.K. Mukherji

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
Responses
References
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

American Journal of Neuroradiology

Vol. 32, Issue 8

1 Sep 2011

Table of Contents
Index by author

Download PDF

Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Trastuzumab (Herceptin)

Message Subject (Your Name) has sent you a message from American Journal of Neuroradiology

Message Body (Your Name) thought you would like to see the American Journal of Neuroradiology web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cite this article

J.J. Gemmete, S.K. Mukherji

Trastuzumab (Herceptin)

American Journal of Neuroradiology Sep 2011, 32 (8) 1373-1374; DOI: 10.3174/ajnr.A2619

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

0 Responses

Respond to this article

Bookmark this article

User Name *

Password *

Remember my user name & password.

Trastuzumab (Herceptin)

J.J. Gemmete, S.K. Mukherji

American Journal of Neuroradiology Sep 2011, 32 (8) 1373-1374; DOI: 10.3174/ajnr.A2619

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Purchase

Jump to section

Article
Figures & Data
Info & Metrics
Responses
References
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture
Improved Detection of HER2 by a Quasi-Targeted Proteomics Approach Using Aptamer-Peptide Probe and Liquid Chromatography-Tandem Mass Spectrometry

Crossref (47)
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits

SEYUNG S. CHUNG, NOLAN GIEHL, YANYUAN WU, JAYDUTT V. VADGAMA

International Journal of Oncology 2014 44 2
Anti-cancer effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis

Asadollahi Parisa, Ghanavati Roya, Rohani Mahdi, Razavi Shabnam, Esghaei Maryam, Talebi Malihe, Salvatore V. Pizzo

PLOS ONE 2020 15 5
Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer

Yiwen You, Zhiyuan Xu, Yun Chen

Drug Delivery 2018 25 1
Charge variant analysis of proposed biosimilar to Trastuzumab

Pravinkumar Dakshinamurthy, Pavithra Mukunda, Bhargav Prasad Kodaganti, Bharath Ravindra Shenoy, Bairavabalakumar Natarajan, Amol Maliwalave, Vivek Halan, Sathyabalan Murugesan, Sunit Maity

Biologicals 2017 46
Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses

Jihun Lee, Hyun Ah Kang, Jin Soo Bae, Kyu Dae Kim, Kyoung Hoon Lee, Ki Jung Lim, Min Joo Choo, Shin Jae Chang

mAbs 2018 10 4
Application of aptamer-drug delivery system in the therapy of breast cancer

Rui Fan, Xufeng Tao, Xiaohan Zhai, Yanna Zhu, Yunming Li, Yanwei Chen, Deshi Dong, Shilei Yang, Linlin Lv

Biomedicine & Pharmacotherapy 2023 161
Current Strategies and Applications for Precision Drug Design

Chen Wang, Pan Xu, Luyu Zhang, Jing Huang, Kongkai Zhu, Cheng Luo

Frontiers in Pharmacology 2018 9
Personalized Drug Therapy: Innovative Concept Guided With Proteoformics

Junwen Su, Lamei Yang, Ziran Sun, Xianquan Zhan

Molecular & Cellular Proteomics 2024 23 3
Attenuation of p53 mutant as an approach for treatment Her2-positive cancer

Olga Fedorova, Alexandra Daks, Oleg Shuvalov, Alena Kizenko, Alexey Petukhov, Yulia Gnennaya, Nikolai Barlev

Cell Death Discovery 2020 6 1
Improved Detection of HER2 by a Quasi-Targeted Proteomics Approach Using Aptamer–Peptide Probe and Liquid Chromatography–Tandem Mass Spectrometry

Weixian Zhou, Feifei Xu, Danni Li, Yun Chen

Clinical Chemistry 2018 64 3

Indexed Content

Current Issue
Accepted Manuscripts
Article Preview
Past Issues
Editorials
Editors Choice
Fellow Journal Club
Letters to the Editor

Cases

Case Collection
Archive - Case of the Week
Archive - Case of the Month
Archive - Classic Case

Special Collections

Special Collections

Resources

News and Updates
Turn around Times
Submit a Manuscript
Author Policies
Manuscript Submission Guidelines
Evidence-Based Medicine Level Guide
Publishing Checklists
Graphical Abstract Preparation
Imaging Protocol Submission
Submit a Case
Become a Reviewer/Academy of Reviewers
Get Peer Review Credit from Publons

Multimedia

AJNR Podcast
AJNR SCANtastic
Video Articles

About Us

About AJNR
Editorial Board
Not an AJNR Subscriber? Join Now
Alerts
Feedback
Advertise with us
Librarian Resources
Permissions
Terms and Conditions

American Society of Neuroradiology

Not an ASNR Member? Join Now

Main menu

User menu

Search

American Journal of Neuroradiology

Trastuzumab (Herceptin)

Plain text

Vertical Tabs

Jump to comment:

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Indexed Content

Cases

Special Collections

Resources

Multimedia

About Us

American Society of Neuroradiology